A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

ClinicalTrials.gov ID: NCT00902928

Public ClinicalTrials.gov record NCT00902928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 Bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.

Study identification

NCT ID: NCT00902928
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Enrollment: 1,992 participants

Conditions and interventions

Conditions

Interventions

YM150 Drug
enoxaparin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2009 (Type not available)
Primary completion: Jun 2010 (Actual)
Completion: Aug 2010 (Actual)
Last update posted: Oct 27, 2015

2009 – 2010

United States locations

U.S. sites: 18
U.S. states: 10
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85023	—
Not listed	Phoenix	Arizona	85050	—
Not listed	Tuscon	Arizona	85712	—
Not listed	Little Rock	Arkansas	72205	—
Not listed	Long Beach	California	90806	—
Not listed	Torrance	California	90507	—
Not listed	Aurora	Colorado	80015	—
Not listed	DeLand	Florida	32720	—
Not listed	Pinellas Park	Florida	33781	—
Not listed	Sarasota	Florida	34239	—
Not listed	Tamarac	Florida	33321	—
Not listed	Meridian	Idaho	83642	—
Not listed	Lexington	Kentucky	40509	—
Not listed	Baltimore	Maryland	21215	—
Not listed	Charleston	South Carolina	29414	—
Not listed	Austin	Texas	78745	—
Not listed	Dallas	Texas	75231	—
Not listed	Houston	Texas	77024	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 138 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00902928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 27, 2015 · Synced Oct 30, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00902928 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →